TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05121714

Intervention type: DRUG
Group type: OTHER
Intervention: Caffeine
Description: This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)

Intervention type: DRUG
Group type: OTHER
Intervention: ABX464
Description: This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).

Intervention type: DRUG
Group type: OTHER
Intervention: ABX464
Description: This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).

Intervention type: DRUG
Group type: OTHER
Intervention: Fluvoxamine
Description: his is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).
Study: NCT01549561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: 16 weeks of parent training led by a trained group facilitator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: 16 weeks of parent training led by a trained group facilitator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Skills Training
Description: 16 weeks of one-on-one sessions with a trained youth skills coach
Study: NCT00565877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound inspection
Description: post-PICC insertion Ultrasound inspection of the ipsilateral neck for PICC in a malposition (ipsilateral internal jugular vein)
Study: NCT01316211

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of coflex™ after surgical decompression
Description: The device will be implanted after surgical decompression in patients with spinal stenosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical decompression
Description: Surgical decompression in patients with spinal stenosis without stabilization by an additional implant
Study: NCT03174873

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopy
Description: Laparoscopy will be done for unexplained infertile couples before starting IVF because not all pathologic lesions that discovered by laparoscope need IVF and so, protect patients from unneeded IVF program
Study: NCT00369538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide, losartan
Description: One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
Study: NCT01606527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600mg orally three times daily
Description: Ibuprofen is taken 600mg orally three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 600mg orally three times daily
Description: Ibuprofen is taken 600mg orally three times daily
Study: NCT01842113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 550mg by mouth twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Lactulose 30ml by mouth three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Placebo
Description: Lactulose Placebo 30ml three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin Placebo
Description: Rifaximin Placebo twice a day
Study: NCT03862287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: See arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.5% Inj_#2
Description: See arm description.
Study: NCT01368146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IV Clear™
Description: Polyurethane film with a silicone adhesive dressing containing chlorhexidine and silver

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm CHG™
Description: Polyurethane film with a polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Silicone Vehicle Control Dressing
Description: Polyurethane film with silicone adhesive dressing, without antimicrobials
Study: NCT04667975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-702
Description: In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-702
Description: In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.
Study: NCT02413060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: This training consists 4 exercises and every exercises lasts 5 seconds.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle counselling
Description: Lifestyle counselling mainly indicates dietary instruction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Description: Lifestyle counselling mainly indicates dietary instruction.
Study: NCT01450748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium alginate
Description: oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
Study: NCT06103214

Intervention type: OTHER
Group type: OTHER
Intervention: acute normovolemic hemodilution (ANH)
Description: Acute normovolemic hemodilution (ANH) is a medical procedure that involves removing a certain volume of blood from a patient before surgery and replacing it with a volume expander or blood substitute. The goal of ANH is to reduce the need for blood transfusions during or after surgery. During the ANH procedure, a patient's blood is typically withdrawn and replaced with a crystalloid or colloid solution. This dilutes the patient's blood, reducing the concentration of red blood cells. The withdrawn blood is then stored and can be reinfused back into the patient after the surgical procedure is completed.
Study: NCT01068067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drug (tacrolimus and SchE) and genetics
Description: Patients were genotyped for the polymorphisms that can influence tacrolimus pharmacokinetics before transplantation. After transplantation, initial tacrolimus dosage was based on an algorism guided by pharmacogenetics and SchE.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: After transplantation, patients received standard initial dose of tacrolimus (0.050-0.075 mg/kg).
Study: NCT01382472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40 mg per operative in PPCI, the 40 daily during hospital stay
Study: NCT06103214

Intervention type: OTHER
Group type: OTHER
Intervention: acute hypervolemic hemodilution (AHH)
Description: The purpose of diluting the blood with fluids and removing some of the red blood cells is to decrease the viscosity of the blood. This can improve blood flow and oxygen delivery to tissues, especially in cases of decreased blood flow or oxygenation.
Study: NCT02740322

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hum Test
Description: The subject will be brought into an exam room. The subject will then be asked to hum for a few seconds in a low pitch. They will then be asked if the nose was heard more so in one ear compared to the other. The subject will then be asked to hum for a few seconds in a high pitch. They will then be asked again if the noise was heard more so in one ear compared to the other.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Weber Test
Description: Using a 512 Hz tuning fork, the tuning fork will be vibrated and placed on the subject's glabella (forehead landmark). The subject will then be asked if the vibration was heard more so in one ear compared to the other.

Intervention type: DEVICE
Group type: OTHER
Intervention: Audiogram
Description: A standard audiogram will be administered by an audiologist.
Study: NCT04492319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Test
Description: spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml 0.9 normal saline in each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml neostigmine 500 μg in each side .
Study: NCT01382472

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin
Description: No statin acutely. Simvastatin 20 mg from day 2.
Study: NCT01856712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
Study: NCT03607357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Oxygen
Description: The initial flow speed is set at 30L/min and increases at 5L/min in titrated type until the patient feels uncomfortable. The temperature is set at 37℃. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-invasive Ventilation
Description: The values of initial pressure are set at a lower level (inspiratory pressure: 6-8cmH2O, expiratory pressure: 4cmH2O) and adjusted to a suitable level in 10-20min. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
Study: NCT03719794

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplement
Description: Probiotic supplement once daily (xyz) for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo supplement once daily for 12 weeks
Study: NCT02541032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive dental treatment
Description: Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dental treatment
Description: Supragingival mechanical scaling and polishing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arestin
Description: To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
Study: NCT01546792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention
Description: Exercise training, dietary advice, behaviour change counselling
Study: NCT01522534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: mepivacaine 1% 20 ml corresponding to 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine alone with a placebo nerve block
Study: NCT03427099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation with a biopsychosocial focus
Description: Rehabilitation with a biopsychosocial focus

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: usual care
Study: NCT04591886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mind. body. voice.
Description: The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
Study: NCT02048826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FINGER I
Description: FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FINGER I
Description: FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FINGER II
Description: FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FINGER II
Description: FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II
Study: NCT02093455

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chardonnay Seed Flour (CSF)
Description: CSF is made from wine grape skins and seeds.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04088370

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood Draw Only

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood Draw Only

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood Draw Only
Study: NCT01180699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine: Vaxigrip or Fluviral and Intanza
Description: Patients will be randomized to receive either one intradermal dose of 0.1 mL or one intramuscular injection of 0.5 mL of the standard influenza vaccine in the deltoid muscle of the nondominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine: Vaxigrip or Fluviral and Intanza
Description: Patients will be randomized to receive either one intradermal dose of 0.1 mL or one intramuscular injection of 0.5 mL of the standard influenza vaccine in the deltoid muscle of the nondominant arm.
Study: NCT03708640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Activity Tracker
Description: Group wears physical activity tracker and receives physical activity feedback information informed by the tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Text Messaging
Description: Group receives personalized, health coaching via smart text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Counseling
Description: Group receives baseline counseling on physical activity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity Counseling
Description: Group receives baseline counseling on physical activity
Study: NCT02525003

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D2 fortified bread
Description: Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
Study: NCT03745222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: PD-1 inhibitor (monoclonal antibody against PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: PD-1 inhibitor (monoclonal antibody against PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (cCRT)
Description: Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (cCRT)
Description: Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Concurrent chemoradiotherapy (cCRT)
Description: Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04797091

Intervention type: OTHER
Intervention: Retrospective data collection
Description: Retrospective data collection to overcome the lack of knowledge on epidemiology, clinical course including diagnostic and therapeutic approaches and prognostic factors for SARS-CoV-2-infections and their complications among nephrology and elderly patients, as well as to serve as a platform for future studies and outbreak situations.

Intervention type: OTHER
Intervention: Retrospective data collection
Description: Retrospective data collection to overcome the lack of knowledge on epidemiology, clinical course including diagnostic and therapeutic approaches and prognostic factors for SARS-CoV-2-infections and their complications among nephrology and elderly patients, as well as to serve as a platform for future studies and outbreak situations.
Study: NCT03074214

Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention
Description: All STEMI patients enrolled will at first receive Device(such as: stent or balloon) treatment for their coronary artery.
Study: NCT01201811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
Study: NCT03074812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation (tDCS) is a commonly used non-invasive form of brain stimulation for studying motor functions in health and disease \[36\]. It involves the attachment of surface electrodes to the scalp through which very small electric currents (1 or 2mA) are applied via a current regulated device. The currents do not produce any sensation. The applied current affects excitability of underlying neural tissue.
Study: NCT02737085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells
Description: Patients receive autologous-derived CD19-targeted CAR-T cells following CD20-targeted CAR-T cells after receiving lymphodepleting chemotherapy.
Study: NCT04284397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ASA
Description: A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: All participants will be tested with no treatment.
Study: NCT03074812

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation (tDCS) is a commonly used non-invasive form of brain stimulation for studying motor functions in health and disease \[36\]. It involves the attachment of surface electrodes to the scalp through which very small electric currents (1 or 2mA) are applied via a current regulated device. The currents do not produce any sensation. The applied current affects excitability of underlying neural tissue.
Study: NCT02796430

Intervention type: OTHER
Intervention: Time needed to start indirect calorimetry measurement
Description: Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.

Intervention type: OTHER
Intervention: Indirect calorimetry measurement
Description: Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
Study: NCT02707458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US.
Study: NCT03842410

Intervention type: DEVICE
Group type: OTHER
Intervention: Single-Incision Sling
Description: Solyx Single-Incision Sling for correction of stress urinary incontinence done in the office.
Study: NCT01677702

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)
Description: Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
Study: NCT00574353

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission
Description: You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.